Ascletis Pharma Inc (1672.HK)

Name: Ascletis Pharma Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-04-07

Latest Quarter

2026-04-07

Revenue

$1.1M

Net Income

-$88.0M

Operating Margin

-17,575.7%

Free Cash Flow

-$344M

Debt / Assets

6.3%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Ascletis Pharma Inc (1672.HK).
Income Statement (Quarterly)	2026-04-07	2025-12-31	2025-06-30	2025-03-31
Revenue	1,081,000	931,199	1,081,000	540,500
Cost of Revenue	960,000	8,572,551	960,000	480,000
Gross Profit	121,000	-7,641,351	121,000	60,500
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	43,302,000	28,746,271	43,302,000	21,651,000
Operating Expenses	190,114,000	281,222,594	190,114,000	95,057,000
Operating Income	-189,993,000	-288,863,946	-189,993,000	-94,996,500
Interest Expense	0	75,714	0	0
Income Before Tax	-87,951,000	-266,894,691	-87,951,000	-43,975,500
Income Tax Expense	0	-497,557	0	0
Net Income	-87,951,000	-267,392,249	-87,951,000	-43,975,500
Per Share
EPS	-0.09	-0.28	-0.09	-0.05
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Ascletis Pharma Inc (1672.HK).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	1,975,512	1,283,000	56,596,000	54,090,000	76,876,000
Cost of Revenue	18,623,204	548,000	30,606,000	78,782,000	37,703,000
Gross Profit	-16,647,691	735,000	25,990,000	-24,692,000	39,173,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	66,872,287	101,744,000	62,963,000	32,414,000	37,363,000
Operating Expenses	454,590,114	296,154,000	326,198,000	314,937,000	223,256,000
Operating Income	-471,237,806	-295,419,000	-306,811,000	-262,817,000	-184,083,000
Interest Expense	159,754	0	144,000	157,000	125,000
Income Before Tax	-350,073,000	-300,936,000	-144,715,000	-314,843,000	-199,017,000
Income Tax Expense	-492,903	0	0	51,869,000	0
Net Income	-350,565,906	-300,936,000	-144,715,000	-366,712,000	-199,017,000
Per Share
EPS	-0.36	-0.30	-0.13	-0.34	-0.19
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Ascletis Pharma Inc (1672.HK).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	1,444,130,569	865,730,000	330,117,000	2,470,834,000
Short Term Investments	457,557,670	1,081,801,000	1,969,286,000	11,200,000
Net Receivables	13,224,654	152,000	4,005,000	23,873,000
Inventory	1,874,801	4,373,000	6,071,000	20,519,000
Total Current Assets	1,921,540,729	1,970,782,000	2,332,756,000	2,544,726,000
Property Plant Equipment	46,981,090	57,074,000	68,277,000	73,041,000
Goodwill and Intangibles	0	12,118,000	26,315,000	16,559,000
Total Assets	2,067,409,109	2,124,572,000	2,491,009,000	2,657,042,000
Liabilities
Account Payables	1,344,574	31,000	649,000	3,135,000
Short Term Debt	2,872,228	6,246,000	5,710,000	2,416,000
Total Current Liabilities	127,646,586	153,053,000	140,679,000	108,189,000
Long Term Debt	2,287,977	1,387,000	2,706,000	1,821,000
Total Liabilities	129,934,564	158,410,000	148,943,000	117,156,000
Shareholders Equity
Retained Earnings	0	-1,475,339,000	-1,174,403,000	-1,029,688,000
Total Shareholders Equity	1,935,091,524	1,966,162,000	2,342,066,000	2,539,886,000

Balance sheet annual history for Ascletis Pharma Inc (1672.HK).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	1,444,130,569	865,730,000	330,117,000	2,470,834,000	2,495,496,000
Short Term Investments	457,557,670	1,081,801,000	1,969,286,000	11,200,000	5,200,000
Net Receivables	13,224,654	152,000	4,005,000	23,873,000	0
Inventory	1,874,801	4,373,000	6,071,000	20,519,000	56,233,000
Total Current Assets	1,921,540,729	1,970,782,000	2,332,756,000	2,544,726,000	2,631,551,000
Property Plant Equipment	46,981,090	57,074,000	68,277,000	73,041,000	77,509,000
Goodwill and Intangibles	0	12,118,000	26,315,000	16,559,000	0
Total Assets	2,067,409,109	2,124,572,000	2,491,009,000	2,657,042,000	2,829,959,000
Liabilities
Account Payables	1,344,574	31,000	649,000	3,135,000	1,054,000
Short Term Debt	2,872,228	6,246,000	5,710,000	2,416,000	1,568,000
Total Current Liabilities	127,646,586	153,053,000	140,679,000	108,189,000	90,971,000
Long Term Debt	2,287,977	1,387,000	2,706,000	1,821,000	1,182,000
Total Liabilities	129,934,564	158,410,000	148,943,000	117,156,000	100,887,000
Shareholders Equity
Retained Earnings	0	-1,475,339,000	-1,174,403,000	-1,029,688,000	0
Total Shareholders Equity	1,935,091,524	1,966,162,000	2,342,066,000	2,539,886,000	2,729,072,000

Cash flow quarterly history for Ascletis Pharma Inc (1672.HK).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-300,936,000	-144,715,000	-314,843,000	-199,017,000
Depreciation & Amortization	20,454,000	18,480,000	30,191,000	29,545,000
Stock Based Compensation	3,003,000	1,331,000	3,193,000	7,130,000
Change in Working Capital	13,787,000	38,526,000	33,807,000	-10,175,000
Operating Cash Flow	-341,579,000	-144,162,000	-142,453,000	-146,930,000
Investing Activities
Capital Expenditure	-2,148,000	-19,158,000	-14,401,000	-7,198,000
Investments	-2,095,000	-6,213,000	-14,401,000	-4,968,000
Investing Cash Flow	978,906,000	149,845,000	-1,297,387,000	-274,492,000
Financing Activities
Debt Repayment	-4,733,000	-2,391,000	-2,223,000	0
Common Stock Issued/Repurchased	-98,531,000	-78,961,000	961,000	-28,689,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-103,508,000	-81,496,000	-1,419,000	-31,098,000
Summary
Free Cash Flow	-343,727,000	-163,320,000	-156,854,000	-154,128,000
Net Change in Cash	534,209,000	-73,651,000	-1,323,643,000	-483,093,000

Cash flow annual history for Ascletis Pharma Inc (1672.HK).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	-300,936,000	-144,715,000	-314,843,000	-199,017,000	-209,241,000
Depreciation & Amortization	20,454,000	18,480,000	30,191,000	29,545,000	27,163,000
Stock Based Compensation	3,003,000	1,331,000	3,193,000	7,130,000	4,612,000
Change in Working Capital	13,787,000	38,526,000	33,807,000	-10,175,000	10,426,000
Operating Cash Flow	-341,579,000	-144,162,000	-142,453,000	-146,930,000	-84,911,000
Investing Activities
Capital Expenditure	-2,148,000	-19,158,000	-14,401,000	-7,198,000	-38,960,000
Investments	-2,095,000	-6,213,000	-14,401,000	-4,968,000	-4,922,000
Investing Cash Flow	978,906,000	149,845,000	-1,297,387,000	-274,492,000	132,297,000
Financing Activities
Debt Repayment	-4,733,000	-2,391,000	-2,223,000	0	0
Common Stock Issued/Repurchased	-98,531,000	-78,961,000	961,000	-28,689,000	-19,601,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	-103,508,000	-81,496,000	-1,419,000	-31,098,000	-21,670,000
Summary
Free Cash Flow	-343,727,000	-163,320,000	-156,854,000	-154,128,000	-123,871,000
Net Change in Cash	534,209,000	-73,651,000	-1,323,643,000	-483,093,000	-84,540,000